Evaluating Prognostic Factors in Newly Diagnosed Multiple Myeloma
Spectrum of Blood Viscosity , Albumin / Fibrinogen Ratio and Red Cell Distribution Width in Newly Diagnosed Multiple Myeloma Patients. Observation Study
This study is testing how certain blood measurements can help predict the outcomes for people who have just been diagnosed with multiple myeloma.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 25 (estimated) |
| Sex | All |
| Sponsor | Assiut University Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Assiut) |
| Trial ID | NCT06095752 on ClinicalTrials.gov |
What this trial studies
This observational study aims to assess the impact of the albumin/fibrinogen ratio, blood viscosity, and red cell distribution width (RDW) on the prognosis of patients newly diagnosed with multiple myeloma (MM). Multiple myeloma is a type of cancer that affects plasma cells in the bone marrow, leading to various health complications. The study will analyze how these specific hematologic indices correlate with patient outcomes, including survival rates and disease progression. By understanding these relationships, the research seeks to enhance prognostic assessments for newly diagnosed MM patients.
Who should consider this trial
Good fit: Ideal candidates for this study are patients who have been newly diagnosed with multiple myeloma according to the International Myeloma Working Group criteria.
Not a fit: Patients who have previously been diagnosed with multiple myeloma and have started treatment or are in post-treatment follow-up will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could improve prognostic evaluations and treatment strategies for patients with multiple myeloma.
How similar studies have performed: While the albumin/fibrinogen ratio has shown promise in previous studies, this specific approach to evaluating multiple prognostic factors in newly diagnosed MM patients is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients newly diagnosed with MM according to International Myeloma Working Group criteria 2016. Exclusion Criteria: * Patient previously diagnosed MM and started treatment or in post treatment follow up
Where this trial is running
Assiut
- Assiut University hospital — Assiut, Egypt (Recruiting)
Study contacts
- Study coordinator: Ahmed Radwan Rostom, Resident Dr
- Email: Ahmedrostomyy@gmail.com
- Phone: 01156900472
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.